Antibody tests can identify people with a resolving or past severe acute respiratory syndrome coronavirus 2 infection and thereby help researchers and public health experts better understand the epidemiology of severe acute respiratory syndrome coronavirus 2. This study is a retrospective study that included 187 Libyan individuals, who attended Attshkhesy (the diagnostic) laboratory in Alkhoms City, Libya, between January 01, 2021, and August 28, 2021. The mean ages of males and females were 48.8 and 46.8, respectively. The study utilized the CLIA quantitative antibody test. To perform the CLIA quantitative antibody test, a high throughput assay apparatus known as the YHLO - iFlash 1800 Chemiluminescence Immunoassay Analyzer was utilized, along with assay reagents called iFlash-SARS-CoV-2 IgM/IgG (manufactured by YHLO Biotech, Shenzhen, China). In female subjects, the concentration of severe acute respiratory syndrome coronavirus 2 IgM was higher than that of IgG in all age groups. Interestingly, in male subjects, the results showed the opposite, where the concentration of severe acute respiratory syndrome coronavirus-2 IgG was much higher than that of IgM in all age groups. When male data were plotted against the female data, the concentration of severe acute respiratory syndrome coronavirus 2 IgM in females was much higher than that of IgM in males in all age groups. Merged IgM-male and IgM-female results showed that IgM concentrations were higher in females than males at all age groups, which means that the incidence of recent COVID-19 infection was higher in females than in males. On the other hand, the IgG antibody prevalence in females was always higher than in males except at age groups 41-50 years and 51-60 years, which can be used as an indicator of high acquired immunity among females due to possible reinfection of females with COVID-19 virus.